The global anatomic pathology market size was valued at USD 30.16 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 8.7% from 2023 to 2030. The growing adoption of biomarkers in clinical settings allows pathologists to gain insights into the molecular-level mechanisms. This valuable information not only helps in clinical decision-making but also contributes to enhancing patient outcomes. As a result, there is a rising dependence on pathology tests and procedures based on biomarkers to examine prevalent malignancies and tumorigenesis. This increasing reliance on biomarker-driven pathology is expected to drive the growth of the market.

The COVID-19 pandemic drove the adoption of whole slide imaging, digital pathology, and telepathology. Digital pathology has helped pathologists work remotely; enhancing their overall productivity and helping them address the backlog of cases. The usage rate of these technologies has been gaining momentum over the past few years. The COVID-19 pandemic has further boosted this adoption, in turn, having a positive impact on the market growth.

The increasing adoption of advanced pathology equipment, including digital microscopes, gross imaging systems, and staining systems, is anticipated to significantly enhance anatomic pathological practices. Digital imaging solutions, in particular, offer significant advantages in terms of specificity and accuracy compared to conventional techniques. As a result, the adoption of these solutions in the market for anatomic pathology is experiencing an upsurge, driven by the increased demand for services that can provide improved diagnostic precision and reliability.

Gather more insights about the market drivers, restrains and growth of the Global Anatomic Pathology Market

Detailed Segmentation:

Product & Services Insights

The consumables segment dominated the market with the largest revenue share of 69.1% in 2022. This segment's prominence can be attributed to multiple factors, including the widespread availability and affordability of pathology consumables. Furthermore, the market's growth is fueled by the extensive accessibility of a diverse range of products within this segment. An array of essential reagents, antibodies, and probes specifically designed for anatomic pathology protocols are being actively marketed. Significant examples of key reagents and kits include the ultra-view SISH DNP Detection Kit , Instrument Cleaning Kit by Agilent, Tamping Tools KitsISH iVIEW Blue Plus Detection Kit by F. Hoffmann-La Roche Ltd, and , CISH Centromere Detection Kits by Thermo Fisher. In May 2023, Sysmex announced the launch of its Clinical Flow Cytometry1 System in Japan, & other antibody reagents including Sample Preparation System PS-10 in regions such as Asia Pacific, and North America. This launch is helpful in contributing to higher efficiency and testing strategies or standards. In September 2022, F. Hoffmann-La Roche Ltd announced the launch of its PRAME (EPR20330) antibody that computes PRAME protein expression and helps to diagnose through tissue sampling from melanoma patients.

End-use Insights

The hospitals segment dominated the market with the largest revenue share of 48.2% in 2022 owing to the high hospitalization rate of cancer patients, coupled with a substantial number of frequent readmissions in hospitals. Moreover, the presence of well-developed infrastructure, coupled with a well-trained staff in hospital-based pathological laboratories, stimulates the growth of the hospital segment. The hospital segment is also expected to be befitted by an increasing number of initiatives undertaken by public and private agencies to promote advanced healthcare systems. In June 2023, Sheikh Shakhbout Medical City (SSMC), a known hospital in the UAE also in joint-venture partnership with Abu Dhabi Health Services Company (SEHA) and Mayo Clinic announced the launch of the Anatomical Pathology Laboratory. It is also known as a state-of-the-art that compliments SSMC’s specialists’ pathology team which helps in the diagnosis of diseases and complicated situations with high efficiency through AI applications and tools.

Application Insights

The disease diagnosis segment dominated the market with the largest revenue share of 59.1% in 2022. Anatomic pathology plays a pivotal role in disease diagnosis, offering researchers an opportunity to delve into disease etiology and associated outcomes. Consequently, the market is experiencing a notable surge in the widespread application of anatomic pathology protocols in disease diagnosis. The primary driving force behind the growth of the disease diagnosis segment is attributed to the escalating prevalence of chronic conditions, particularly cancer, and the rising proportion of elderly individuals within the population. These factors collectively contribute to the increased demand for accurate and comprehensive disease diagnosis facilitated by anatomic pathology practices. For instance, in March 2023, PathAI, an AI-powered pathology company, launched its AISight, which helps to evaluate the percentage of PD-L1 positive tumors and immune cells in lung cancer. PathAI's network of laboratories will take part in the revolution of anatomic pathology and will have access to its extensive and growing algorithm products across oncology and non-oncology. The anatomic pathology workflow aids the detection of a tumor at the inflammatory and proliferating stromal cells stage, thus minimizing costs associated with tumor eradication. In addition, the increasing focus of the manufacturers on the introduction of innovative and novel diagnostics techniques accelerates segment growth.

Regional Insights

North America dominated the market and accounted for the largest revenue share of 44.9% in 2022. The region is anticipated to continue its dominance over the forecast period. This growth can be attributed to the presence of well-established players the, growing implementation of digital pathology services with advanced imaging tools, rising awareness about regular health screening, and favorable government reimbursement policies. Efforts by key players for maintaining their share drive the U.S. market to a dominant position. For instance, In September 2021, Agilent Technologies announced a partnership with Visiopharm to expand its (AI)-driven precision pathology software globally. Such partnerships are anticipated to supplement market growth. In April 2021, Abbott Laboratories announced a partnership with Walgreens Boots Alliance to offer affordable healthcare services at ease such as medical consultation, and diagnostic tests in the U.S.

Browse through Grand View Research's Healthcare Industry Research Reports.

Key Companies & Market Share Insights

Anatomic pathology is a mature industry with a large number of key players in it. The advent of new strategic plans to maintain competitiveness stimulates market growth. The market is well equipped with upcoming and innovative instruments and consumables to address the challenges in transforming pathology trends. For instance, in June 2022, EmeritusDX, a known cancer diagnostic & information company, acquired Freedom Pathology Partners to increase its reach and uplift its presence nationally in the Anatomic Pathology, Molecular testing, and Fluorescence in situ Hybridization.

Additionally, in September 2021, F. Hoffmann-La Roche Ltd announced the launch of digital pathology open environment. The new workflow allows researchers and physicians to share images for better analysis. Further, the platform is compatible with whole slide imaging technology. Similarly, in May 2021, F. Hoffmann-La Roche Ltd announced the merger with GenMark to expand and uplift its molecular diagnostic portfolio through GenMark’s ePlex system which will boost Roche’s work in managing antibiotic resistance and infectious diseases. Hence, the ongoing strategies adopted by key players boost the market growth as it helps retain their leadership in the market. Some prominent players in the global anatomic pathology market include:

Order a free sample PDF of the Anatomic Pathology Market Intelligence Study, published by Grand View Research.